{
  "id": 6652659,
  "title": "COMPASS Pathways at cantor healthcare conference: launch path sharpens",
  "url": "https://urgent.news/2026/09/10/compass-pathways-at-cantor-healthcare-conference-launch-path-sharpens",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-10T21:32:38.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/transcripts/compass-pathways-at-cantor-healthcare-conference-launch-path-sharpens-93CH-4896996"
  },
  "original_language": "en",
  "account": "COMPASS Pathways, a biotech company focused on developing psychedelic-based treatments, shared updates on its psilocybin-based treatment COMP360 at the 12th Annual Cantor Fitzgerald Global Healthcare Conference. The company seeks to establish a clear path to market and reimbursement for COMP360, which is being developed for treatment-resistant depression (TRD) and poses execution risks tied to the FDA timeline, rescheduling, and payer access.\n\nCOMP360 showed a 3 to 4 point MADRS advantage over placebo and a single dose of esketamine in Phase 2 trials, with separation becoming apparent after 24 hours and lasting up to a year. The treatment is expected to require only 2 to 4 doses per year, significantly fewer than SPRAVATO, which demands 25 to 50 administrations annually. COMP360 is currently in a rolling FDA submission process for TRD, with completion anticipated in Q4 2024. The FDA has already begun reviewing parts of the application and has granted the company a National Priority Voucher for accelerated review.\n\nCOMP360's advantages over SPRAVATO include lower dosing frequency, a potentially shorter treatment duration, and an alternative treatment model. The company argues that COMP360's session length, 6-hour monitored quiet sessions, is more operationally simplified than SPRAVATO's frequent short visits. The company has developed new CPT codes to capture the full value of the visit, including work and practice expenses, which should lead to stronger provider reimbursement.\n\nCOMPASS is also pursuing a late-stage, potentially registrational Phase III study in PTSD, a large and underserved market. The company expects patients to need an average of 2 to 4 doses per year, with a per-dose pricing approach and payer negotiations for formulary access. Management expects COMP360 to be the first psychedelic medicine to reach the market, positioning COMPASS as the leading company in the psychedelic space.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}